和铂医药(02142.HK)就治疗促皮质素释放激素医药产品授出全球独家授权

阿斯达克财经

2025/02/26

和铂医药-B(02142.HK) 公布，公司孵化的创新型生物技术公司HBM Alpha Therapeutics (HBMAT)已与一名业务伙伴订立授权及合作协议，以推进治疗多种疾病的促皮质素释放激素(CRH)的新型疗法。据此，业务伙伴获授予在全球范围内(不包括大中华区，即中国、台湾、香港及澳门)开发任何包含或含有HBM9013的医药产品的独家授权。HBMAT有权获得总计高达3.95亿美元的首付款...

网页链接

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2514027392"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2514027392\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2514027392?lang=zh_CN&edition=fundamental","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20210504112141113_s.jpg","is_english":false,"pubTime":"2025-02-26 09:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2514027392","market":"hk","top_or_hot":-1,"title":"和铂医药(02142.HK)就治疗促皮质素释放激素医药产品授出全球独家授权","media":"阿斯达克财经","content":"<div>\n<p>和铂医药-B(02142.HK) 公布，公司孵化的创新型生物技术公司HBM Alpha Therapeutics (HBMAT)已与一名业务伙伴订立授权及合作协议，以推进治疗多种疾病的促皮质素释放激素(CRH)的新型疗法。据此，业务伙伴获授予在全球范围内(不包括大中华区，即中国、台湾、香港及澳门)开发任何包含或含有HBM9013的医药产品的独家授权。HBMAT有权获得总计高达3.95亿美元的首付款...</p>\n\n<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1420222/latest-news/AAFN\">网页链接</a>\n\n</div>\n","source":"aastocks_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>和铂医药(02142.HK)就治疗促皮质素释放激素医药产品授出全球独家授权</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n和铂医药(02142.HK)就治疗促皮质素释放激素医药产品授出全球独家授权\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-02-26 09:33 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1420222/latest-news/AAFN><strong>阿斯达克财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>和铂医药-B(02142.HK) 公布，公司孵化的创新型生物技术公司HBM Alpha Therapeutics (HBMAT)已与一名业务伙伴订立授权及合作协议，以推进治疗多种疾病的促皮质素释放激素(CRH)的新型疗法。据此，业务伙伴获授予在全球范围内(不包括大中华区，即中国、台湾、香港及澳门)开发任何包含或含有HBM9013的医药产品的独家授权。HBMAT有权获得总计高达3.95亿美元的首付款...</p>\n\n<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1420222/latest-news/AAFN\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02142","symbol_name":"和铂医药-B","start_time":0,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1420222/latest-news/AAFN","article_id":"2514027392","we_media_id":null,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20210504112141113_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1420222/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2514027392","pubTimestamp":1740533580,"columns":[],"sourceInfo":{"source_id":"aastocks_highlight","name":"阿思達克財經"},"weMediaInfo":null,"summary":"和铂医药-B公布，公司孵化的创新型生物技术公司HBM Alpha Therapeutics 已与一名业务伙伴订立授权及合作协议，以推进治疗多种疾病的促皮质素释放激素的新型疗法。据此，业务伙伴获授予在全球范围内开发任何包含或含有HBM9013的医药产品的独家授权。此外，HBMAT亦有权获得认股权证以收取业务伙伴的少数股权。HBM9013/HAT001是集团开发的一项抗CRH抗体疗程，旨在治疗CRH相关疾病，包括先天性肾上腺增生症及其他疾病。","collect":0,"end_time":0,"defaultTopTitle":"aastocks.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"159938":"医药","02142":"和铂医药-B","BK1515":"抗疫概念","BK1161":"生物科技","BK1574":"生物医药B类股","09939":"开拓药业-B","BK1583":"高瓴概念"},"translate_title":"Hebo Pharmaceuticals (02142. HK) grants exclusive global license for therapeutic corticotropin-releasing hormone pharmaceutical products","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159938":1,"02142":1,"09939":1},"content_text":"和铂医药-B(02142.HK) 公布，公司孵化的创新型生物技术公司HBM Alpha Therapeutics (HBMAT)已与一名业务伙伴订立授权及合作协议，以推进治疗多种疾病的促皮质素释放激素(CRH)的新型疗法。据此，业务伙伴获授予在全球范围内(不包括大中华区，即中国、台湾、香港及澳门)开发任何包含或含有HBM9013的医药产品的独家授权。HBMAT有权获得总计高达3.95亿美元的首付款及潜在里程碑付款，以及于特许使用权期限内基于净销售额的个位数百分比的分级特许权使用费。此外，HBMAT亦有权获得认股权证以收取业务伙伴的少数股权。HBM Alpha Therapeutics是一家开发针对罕见遗传疾病先天性肾上腺增生症(CAH)和多囊型卵巢综合症(PCOS)抗体疗法的公司，其疗法亦适用于与下丘脑－垂体－肾上腺轴(HPA)调节及功能异常相关的其他内分泌疾病。HBM9013/HAT001是集团开发的一项抗CRH抗体疗程，旨在治疗CRH相关疾病，包括先天性肾上腺增生症及其他疾病。(jl/da)(港股报价延迟最少十五分钟。)AASTOCKS新闻","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}